CompletedNCT01515423
Monthly or Three-Month Paliperidone Injections for Schizophrenia
About this title
Read the official source — NCT01515423Medication studyAges 18–70Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 173 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,429
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT01515423
- Official title
Show the full official title
A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock, United States · Glendale, United States · Long Beach, United States
173 more locations
- Oakland, United States
- Oceanside, United States
- Orange, United States
- San Diego, United States
- New Britain, United States
- Bradenton, United States
- Kissimmee, United States
- Tampa, United States
- Wichita, United States
- East Lansing, United States
- St Louis, United States
- Las Vegas, United States
- Jamaica, United States
- Durham, United States
- Canton, United States
- Oklahoma City, United States
- Philadelphia, United States
- Charleston, United States
- Memphis, United States
- Austin, United States
- Bothell, United States
- Buenos Aires, Argentina
- Córdoba, Argentina
- Rosario, Argentina
- Elizabeth Vale, Australia
- Frankston, Australia
- Innsbruck, Austria
- Assebroek, Belgium
- Bertrix, Belgium
- Dave, Belgium
- Heusden, Belgium
- Jette, Belgium
- Marchienne-au-Pont, Belgium
- Sint-Denijs-Westrem, Belgium
- Rio de Janeiro, Brazil
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Radnevo, Bulgaria
- Sofia, Bulgaria
- Calgary, Canada
- Halifax, Canada
- Montreal, Canada
- Burlington, Canada
- Baoding, China
- Beijing, China
- Changsha, China
- Guangdong, China
- Guangzhou, China
- Hangzhou, China
- Kunming, China
- Shanghai, China
- Tianjin, China
- Wuhan, China
- Xi'an, China
- Brno, Czechia
- Hořovice, Czechia
- Liberec, Czechia
- Prague, Czechia
- Přerov, Czechia
- Clermont-Ferrand, France
- Dole, France
- Montpellier, France
- Toulon, France
- Bochum, Germany
- Gelsenkirchen, Germany
- Hamburg, Germany
- Heidelberg, Germany
- München, Germany
- Arta, Greece
- Athens, Greece
- Katerini, Greece
- Balassagyarmat, Hungary
- Budapest, Hungary
- Gyõr, Hungary
- Kalocsa, Hungary
- Sopron, Hungary
- Aizu-Wakamatsu, Japan
- Fujioka, Japan
- Fujisawa, Japan
- Hadano, Japan
- Himeji, Japan
- Hitachi, Japan
- Ichikawa, Japan
- Kanuma, Japan
- Kanzaki, Japan
- Kashihara, Japan
- Kashiwara, Japan
- Kasuya, Japan
- Kawasaki, Japan
- Kitagunma, Japan
- Kochi, Japan
- Kodaira, Japan
- Kumagaya, Japan
- Kumamoto, Japan
- Kure, Japan
- Matsusaka, Japan
- Mitaka, Japan
- Moriguchi, Japan
- Nagasaki, Japan
- Naha, Japan
- Nirasaki, Japan
- Ohta, Japan
- Okayama, Japan
- Okinawa, Japan
- Sakai, Japan
- Shibukawa, Japan
- Takatsuki, Japan
- Toki, Japan
- Tokushima, Japan
- Tokyo, Japan
- Toyoake, Japan
- Ueda, Japan
- Yatsushiro, Japan
- Yokkaichi, Japan
- Yokohama, Japan
- Guadalajara, Mexico
- Monterrey, Mexico
- Tlalnepantla, Mexico
- Bełchatów, Poland
- Bydgoszcz, Poland
- Chełmno, Poland
- Gdynia Na, Poland
- Lubin, Poland
- Lubliniec, Poland
- Piekary Śląskie, Poland
- Torun, Poland
- Ząbki, Poland
- Almada, Portugal
- Angra do Heroísmo, Portugal
- Coimbra, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Brasov, Romania
- Cluj-Napoca, Romania
- Arkhangelsk, Russia
- Gatchina, Russia
- Krasnodar, Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Smolensk, Russia
- Smolensk Region N/A, Russia
- St-Peterburg, Russia
- Tomsk Na, Russia
- Yaroslavl, Russia
- Yekaterinburg, Russia
- Bratislava, Slovakia
- Michalovce, Slovakia
- Rimavská Sobota, Slovakia
- Trenčín, Slovakia
- Busan, South Korea
- Gwangju, South Korea
- Gyeonggi-do, South Korea
- Seoul, South Korea
- Alicante, Spain
- Barakaldo, Spain
- Barcelona, Spain
- Coslada, Spain
- Elche, Spain
- Madrid, Spain
- Zamora, Spain
- Uppsala, Sweden
- Bali Township, Taipei County, Taiwan
- Kaohsiung City, Taiwan
- Taoyuan, Taiwan
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Czechia
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid), PP1M 50 mg eq., PP1M 75 mg eq., PP1M 100 mg eq. and PP1M 150 mg eq..
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia